SHANGHAI FOSUN PHARMACEUTICAL Aktie

 

Citi wrote in its research report that it had had a meeting with Guan Xiaohui, Co-Chairman of FOSUN PHARMA (02196.HK). Considering the company's attractive employee stock ownership plan targets, innovative pipeline valuation, and potential operational leverage effects, the broker raised its target price from HKD25 to HKD35.3......

Shanghai Henlius Biotech is in talks with multinational pharmaceutical firms including Johnson & Johnson and Roche Holding about selling them the rights to an experimental cancer drug, people familiar with the matter said. An agreement could fetch the subsidiary of Shanghai Fosun Pharmaceutical at least several hundred million dollars up front and then more in milestone payments down the road based on the drug's performance, the people said. They asked not to be identified because the......

At midday close, HSI rose 90 pts or 0.4% to 25,508. HSTI rose 15 pts or 0.3% to 5,702. HSCEI gained 15 pts or 0.2% to 9,072.Active Heavyweights:BABA (09988.HK) closed at $136.7, up 3.7%XIAOMI (01810.HK) closed at $54.3, up 1.2%TENCENT (00700.HK) closed at $612, up 1.1%MEITUAN (03690.HK) closed at $102.5, down 0.5%HSI & HSCEI Con......

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company,......

FOSUN PHARMA (02196.HK) opened up 7.55% today and once peaked at HKD21.16. It last traded at HKD20.66, up 6.83%, on a volume of 6.4764 million shares and a turnover of HKD135 million.The company announced yesterday (11th) that its controlling subsidiary, Fosun Pharmaceutical Industrial, has granted Expedition the rights to devel......

Following a joint U.S.-China statement announcing a further 90-day suspension of reciprocal 24% tariffs, Hong Kong bourse opened lower as markets awaited U.S. inflation data. The HSI dipped 82 points or 0.3% to 24,824, the HSCEI dropped 30 points or 0.3% to 8,858, and the HSTECH declined 32 points or 0.6% to 5,427.For techs, BAB......

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement with Expedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and......

Das Instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY wird ex Dividende/Zinsen gehandelt am 24.07.2025 The instrument 08HH CNE100001M79 SHANG.FOS.PHARM.GR.H YC 1 EQUITY has its ex-dividend/interest day on 24.07.2025...

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

LEHI, Utah, June 26, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the pricing of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”). The shares of common stock are being sold at a price of $12.00 per share. The offering is expected to close on June 27, 2025, subject to customary closing conditions....

LEHI, Utah, June 25, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ: NATR) (“Nature's Sunshine” or the “Company”), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the launch of an underwritten secondary public offering of up to 2,854,607 shares of its common stock to be sold by Fosun Pharma USA, Inc (the “Selling Stockholder”)....

PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Monday said that they have partnered to develop TEV-56278.Teva's TEV-56278 ut......

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages......

FOSUN PHARMA (02196.HK)(600196.SH) announced that it repurchased a total of 800,300 shares of the company on the Shanghai Stock Exchange today (6th), with the price per share ranging from RMB24.92 to RMB25.14, involving a total of approximately RMB19.9988 million. ~AASTOCKS Financial NewsWebsite: www.aastocks.com...

FOSUN PHARMA (02196.HK) opened up 2.27% today (30th) and once surged by 10.3% to a peak of HKD16.5. It last traded at HKD16.38, up 9.49%, on a volume of 30.4045 million shares, involving HKD488 million.Shanghai Fosun Pharmaceutical Industrial, a subsidiary of Fosun Pharmaceutical, has received approval from China's National ......

Stock│Forecast for Percentage of Revenue from Export to US in 2025COWELL (01415.HK)│30%ASMPT(00522.HK)│15%BYD ELECTRONIC (00285.HK)│around 25-30%.KLN (00636.HK)│15-20%AAC TECH (02018.HK)│12%FOSUN PHARMA (02196.HK)│11%SUNNY OPTICAL (02382.HK)│9%Q TECH (01478.HK)│<1%CHERVON ......

FOSUN PHARMA (02196.HK) announced a strategic partnership with Saudi Arabia’s Fakeeh Care Group, an integrated healthcare group, to jointly promote biologics, CAR-T cell therapies, and other cutting-edge treatments in Saudi Arabia, accelerating local medical innovation. Guo Guangchang, Chairman of Fosun International, expr......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY SHANGHAI, March 25, 2025 /PRNewswire/ -- On March 25, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"or "the Group"; Stock Code: 600196.SH, 02196.HK), a leading global......